Abstract
IL-10 is an anti-inflammatory cytokine widely regarded as an inhibitor of immunity. Thus IL-10 and IL-10 antagonist have been proposed as promising therapeutic factors for the treatment of inflammatory diseases and pathogen infections. Here the potential risk of favoring secondary pathogen infections with these therapies is underscored.
Keywords: IL-10, IL-10 antagonists, Immunotherapy
Letters in Drug Design & Discovery
Title: Caveats Regarding the Use of IL-10 and IL-10 Antagonist as Immunotherapeutic Factors
Volume: 4 Issue: 7
Author(s): Jesus Colino
Affiliation:
Keywords: IL-10, IL-10 antagonists, Immunotherapy
Abstract: IL-10 is an anti-inflammatory cytokine widely regarded as an inhibitor of immunity. Thus IL-10 and IL-10 antagonist have been proposed as promising therapeutic factors for the treatment of inflammatory diseases and pathogen infections. Here the potential risk of favoring secondary pathogen infections with these therapies is underscored.
Export Options
About this article
Cite this article as:
Colino Jesus, Caveats Regarding the Use of IL-10 and IL-10 Antagonist as Immunotherapeutic Factors, Letters in Drug Design & Discovery 2007; 4 (7) . https://dx.doi.org/10.2174/157018007781788552
DOI https://dx.doi.org/10.2174/157018007781788552 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Resistance in Cancer: A Target for Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Synthesis of Novel Coumarin Derivatives 7,8-Fused onto Thiazole
Letters in Organic Chemistry Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool?
Current Pharmaceutical Design Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Current Cancer Drug Targets A Dilemma of Functional Genomics: Count the Chickens or Study their Eggs ?
Current Genomics